Immunome Inc. (IMNM) News
Filter IMNM News Items
IMNM News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
IMNM News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest IMNM News From Around the Web
Below are the latest news stories about IMMUNOME INC that investors may wish to consider to help them evaluate IMNM as an investment opportunity.
Hummingbird Bioscience Licenses Novel Antibodies to ImmunomeSAN FRANCISCO and SINGAPORE, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Hummingbird Bioscience, a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat diseases, today announced it has granted Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, an exclusive, worldwide license to monoclonal antibodies that are directed to a single undisclosed target. Under the terms of the |
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOTHELL, Wash., January 02, 2025--Immunome, Inc. (the "Company") (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on January 2, 2025, the Compensation Committee of the Company’s Board of Directors (the "Compensation Committee") granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 45,000 shares of common stock to four new employees under the Company’s 2024 Induc |
Immunome to Present at the Piper Sandler 36th Annual Healthcare ConferenceBOTHELL, Wash., November 27, 2024--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome’s management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024 at 4:30 p.m. Eastern time. |
Immunome Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsImmunome ( NASDAQ:IMNM ) Third Quarter 2024 Results Key Financial Results Revenue: US$2.91m (down 18% from 3Q 2023... |
Immunome, Inc. (IMNM) Reports Q3 Loss, Misses Revenue EstimatesImmunome (IMNM) delivered earnings and revenue surprises of -30% and 19.05%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |
Immunome Reports Third Quarter 2024 Financial Results and Provides Business UpdateBOTHELL, Wash., November 13, 2024--Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update |
ImmunityBio (IBRX) Reports Q3 Loss, Tops Revenue EstimatesImmunityBio (IBRX) delivered earnings and revenue surprises of 22.22% and 39.89%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |
Immunome to Present at Guggenheim’s Inaugural Healthcare Innovation ConferenceBOTHELL, Wash., November 05, 2024--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and CEO of Immunome, will participate in a fireside chat at Guggenheim’s Inaugural Healthcare Innovation Conference on Wednesday, November 13th at 10:30am Eastern Time. |
Immunome Advances with Strategic Asset Acquisition and AgreementImmunome ( (IMNM) ) has shared an announcement. Immunome, Inc. has secured a pivotal asset purchase from Zentalis Pharmaceuticals, acquiring a license for innovative antibody-drug conjugate technology. This strategic move involves issuing shares to Zentalis and a potential $5 million payment upon reaching a developmental milestone. A stock issuance agreement includes restrictions on Zentalis’s trading activities, ensuring stability in Immunome’s stock performance. While forward-looking statement |
Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021BOTHELL, Wash., October 29, 2024--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, recently presented promising preclinical data for IM-1021 and the associated proprietary ADC payload HC74. The results were presented in a poster entitled "Preclinical evaluation of IM-1021, a ROR1-targeted antibody-drug conjugate with a novel topoisomerase I linker payload" at the 36th EORTC-NCI-AACR Symposium on Molecular Tar |